Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia (MURANO)

Phase 3 randomized venetoclax-rituximab vs bendamustine-rituximab in relapsed/refractory CLL, establishing fixed-duration Ven-R and high rates of undetectable MRD that were further analyzed in Kater et al., J Clin Oncol 2019 (PMID 30523712). Level 2.

N Engl J MedPubMed 29562156